BR112023017689A2 - Método de tratamento de uma condição com o uso de uma dose terapeuticamente eficaz do inibidor de malt1 jnj-67856633 (1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil)-n­(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida) - Google Patents

Método de tratamento de uma condição com o uso de uma dose terapeuticamente eficaz do inibidor de malt1 jnj-67856633 (1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil)-n­(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida)

Info

Publication number
BR112023017689A2
BR112023017689A2 BR112023017689A BR112023017689A BR112023017689A2 BR 112023017689 A2 BR112023017689 A2 BR 112023017689A2 BR 112023017689 A BR112023017689 A BR 112023017689A BR 112023017689 A BR112023017689 A BR 112023017689A BR 112023017689 A2 BR112023017689 A2 BR 112023017689A2
Authority
BR
Brazil
Prior art keywords
trifluoromethyl
effective dose
carboxamide
pyridin
oxo
Prior art date
Application number
BR112023017689A
Other languages
English (en)
Inventor
T Greway Anthony
E Willemin Marie
C Wilde Thomas
Ulrike Philippar
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112023017689A2 publication Critical patent/BR112023017689A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

método de tratamento de uma condição com o uso de uma dose terapeuticamente eficaz do inibidor de malt1 jnj-67856633 (1-(1-oxo-1,2-di-hidroiso- quinolin-5-il)-5-(trifluorometil)-n-(2-(trifluorometil)pi-ridin-4-il)-1h-pirazol-4-carboxamida). a invenção refere-se a um método de tratamento de um distúrbio ou uma condição que é afetada pela inibição de malt1 em um indivíduo em necessidade de tratamento que compreende administrar uma dose terapeuticamente eficaz de 1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil)-n-[2-(trifluorometil)piridin-4-il]-1h-pirazol-4-carboxamida (composto a), ou um solvato ou uma forma de sal farmaceuticamente aceitável do mesmo, ao dito indivíduo, em que a dita dose terapeuticamente eficaz é definida no relatório descritivo.
BR112023017689A 2021-03-03 2021-03-03 Método de tratamento de uma condição com o uso de uma dose terapeuticamente eficaz do inibidor de malt1 jnj-67856633 (1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil)-n­(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida) BR112023017689A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2021/051776 WO2022185097A1 (en) 2021-03-03 2021-03-03 Method of treating a condition using a therapeutically effective dose of the malt1 inhibitor jnj -67856633 (1 -(1 -oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1 h-py razole-4-carboxamide)

Publications (1)

Publication Number Publication Date
BR112023017689A2 true BR112023017689A2 (pt) 2023-11-14

Family

ID=74860360

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023017689A BR112023017689A2 (pt) 2021-03-03 2021-03-03 Método de tratamento de uma condição com o uso de uma dose terapeuticamente eficaz do inibidor de malt1 jnj-67856633 (1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil)-n­(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida)

Country Status (8)

Country Link
EP (1) EP4301364A1 (pt)
JP (1) JP2024508890A (pt)
KR (1) KR20230154227A (pt)
CN (1) CN117279639A (pt)
AU (1) AU2021431485A1 (pt)
BR (1) BR112023017689A2 (pt)
CA (1) CA3212339A1 (pt)
WO (1) WO2022185097A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023125877A1 (zh) * 2021-12-30 2023-07-06 上海翰森生物医药科技有限公司 三并环类衍生物抑制剂、其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
PE20212323A1 (es) * 2019-02-22 2021-12-14 Janssen Pharmaceutica Nv Formulaciones farmaceuticas
US20220127249A1 (en) 2019-02-22 2022-04-28 Janssen Pharmaceutica Nv Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate

Also Published As

Publication number Publication date
EP4301364A1 (en) 2024-01-10
WO2022185097A1 (en) 2022-09-09
JP2024508890A (ja) 2024-02-28
AU2021431485A1 (en) 2023-10-19
KR20230154227A (ko) 2023-11-07
CA3212339A1 (en) 2022-09-09
CN117279639A (zh) 2023-12-22

Similar Documents

Publication Publication Date Title
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CO2022012975A2 (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
CO2019006865A2 (es) Nuevos derivados de fenilo
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
BR112016008080A8 (pt) sal de composto heterocíclico contendo nitrogênio ou cristal do mesmo, composição farmacêutica e inibidor de flt3
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
EA200870087A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных в качестве нейропротективных агентов
BR112018069515A2 (pt) uso de masitinibe para tratamento de uma subpopulação de pacientes com esclerose lateral amiotrófica
RU2019100037A (ru) Способ лечения рассеянного склероза с использованием ингибитора lsd1
UY38096A (es) Inhibidores de arginasa y sus métodos de uso
AR119158A1 (es) Tratamientos de angioedema hereditario
BR112017006272A2 (pt) composição farmacêutica para tratar colite ulcerativa.
BR112018075206A2 (pt) tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
RU2012112396A (ru) Ингибиторы киназы, их пролекарственные формы и их применение в терапии
BR112023017689A2 (pt) Método de tratamento de uma condição com o uso de uma dose terapeuticamente eficaz do inibidor de malt1 jnj-67856633 (1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil)-n­(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida)
AR080472A1 (es) Terapias de inhibidor de autofagia basado en tioxantona para tratar el cancer
BRPI0807940B8 (pt) usos de ácido 3´-{n´-[1-(3,4-dimetilfenil)-3-metil-5-oxo-1,5-diidropirazol-4-ilideno]-hidrazino}-2´-hidroxibifenil-3-carboxílico e/ou de um sal farmaceuticamente aceitável do mesmo para o tratamento de câncer e de uma síndrome pré-cancerosa e composição farmacêutica que compreende dito ácido
CO2022000426A2 (es) Inhibidores de calicreína plasmática
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
AR114732A1 (es) Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco
BR112023017648A2 (pt) Terapia de combinação com o uso de um inibidor de malt1 e um inibidor de btk
CL2021003303A1 (es) Tratamiento para sinucleinopatías.